Springworks Therapeutics (SWTX) reported a Q4 net loss Thursday of $1.04 per share, narrowing from a net loss of $1.44 a year earlier.
Analysts polled by FactSet expected a loss of $0.71.
Net product revenue for the quarter ended Dec. 31 was $61.5 million. The previous year's numbers were not provided.
Three analysts surveyed by FactSet expected product revenue of $61.7 million.
The biopharmaceutical company held cash and cash equivalents worth $461.9 million as of Dec. 31. Two analysts polled by FactSet expected $466.8 million.
Shares of the company were up more than 10% in recent premarket activity.
Price: 61.80, Change: +6.07, Percent Change: +10.89
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。